CURA Diagnostics successfully participated in the 2026 conference hosted by the National Drug and Alcohol Screening Association, where the company officially launched its next-generation oral fluid (OF) testing solution.

The new platform features a "one sample, two workflows" approach, enabling both on-site rapid screening and confirmatory laboratory testing from a single specimen. The integrated solution includes a patented collection device, high-sensitivity rapid tests, and comprehensive lab testing powered by proprietary automation and magnetic bead–based extraction (mSPE) technology.

CURA's booth was among the most visited at the expo, reflecting strong industry interest in streamlined, end-to-end oral fluid testing solutions. Conference presentations further reinforced the growing momentum behind oral fluid testing, highlighting its ability to detect higher positivity rates compared to traditional urine-based methods due to directly observed collection and reduced adulteration risk.

CURA Diagnostics is committed to working with industry partners to accelerate the adoption of modern drug testing solutions, helping to build safer workplaces and healthier communities.